Efficacy and cost‐effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high‐risk liver transplant recipients

Julius Balogh, Sherilyn Gordon Burroughs, Maha Boktour, Samir Patel, Ashish Saharia, Robert A. Ochoa, Robert McFadden, David W. Victor, Victor Ankoma‐Sey, Joseph Galati, Howard P. Monsour, Victor Fainstein, Xian C. Li, Kevin A. Grimes, A. Osama Gaber, Thomas Aloia, R. Mark Ghobrial – 29 October 2015 – Aspergillus infection remains a significant and deadly complication after liver transplantation (LT).

Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct‐acting antiviral

Benoit Callendret, Heather B. Eccleston, William Satterfield, Stefania Capone, Antonella Folgori, Riccardo Cortese, Alfredo Nicosia, Christopher M. Walker – 29 October 2015 – Exhaustion of antiviral CD8+ T cells contributes to persistence of hepatitis C viral (HCV) infection. This immune response has proved difficult to restore by therapeutic vaccination, even when HCV replication is suppressed using antiviral regimens containing type I interferon.

Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct‐acting antiviral

Benoit Callendret, Heather B. Eccleston, William Satterfield, Stefania Capone, Antonella Folgori, Riccardo Cortese, Alfredo Nicosia, Christopher M. Walker – 29 October 2015 – Exhaustion of antiviral CD8+ T cells contributes to persistence of hepatitis C viral (HCV) infection. This immune response has proved difficult to restore by therapeutic vaccination, even when HCV replication is suppressed using antiviral regimens containing type I interferon.

Cost‐effectiveness of active‐passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection

Lin Fan, Kwame Owusu‐Edusei, Sarah F. Schillie, Trudy V. Murphy – 28 October 2015 – In an era of antiviral treatment, reexamination of the cost‐effectiveness of strategies to prevent perinatal hepatitis B virus (HBV) transmission in the United States is needed. We used a decision tree and Markov model to estimate the cost‐effectiveness of the current U.S. strategy and two alternatives: (1) Universal hepatitis B vaccination (HepB) strategy: No pregnant women are screened for hepatitis B surface antigen (HBsAg).

Subscribe to